Evidence map›Paper›PMID 29568390›Full record

ArticleOncotarget2018

Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors.

Sergey Malchenko, Simone T Sredni, Jerusha Boyineni, Yingtao Bi, Naira V Margaryan, Maheedhara R Guda, Yulia Kostenko, Tadanori Tomita, Ramana V Davuluri, Kiran Velpula and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Targeting cancer stem cells from a metabolic perspective.Experimental biology and medicine (Maywood, N.J.) · 2020
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Sergey MalchenkoDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
Simone T SredniDepartment of Surgery, Division of Pediatric Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Jerusha BoyineniDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
Yingtao BiDepartment of Preventive Medicine, Division of Health and Biomedical Informatics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Naira V MargaryanDepartment of Biochemistry, Robert C. Byrd Health Sciences Center and Cancer Institute, West Virginia University, Morgantown, West Virginia, United States of America.
Maheedhara R GudaDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
Yulia KostenkoDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
Tadanori TomitaDepartment of Surgery, Division of Pediatric Neurosurgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Ramana V DavuluriDepartment of Preventive Medicine, Division of Health and Biomedical Informatics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Kiran VelpulaDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
Mary J C HendrixDepartment of Biochemistry, Robert C. Byrd Health Sciences Center and Cancer Institute, West Virginia University, Morgantown, West Virginia, United States of America.
Marcelo B SoaresDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine, Peoria, Illinois, United States of America.
University of Illinois Urbana-Champaign · USNorthwestern University · USIllinois College · USWest Virginia University · USLurie Children's Hospital · US

Funding

Informatics Platform for Mammalian Gene Regulation at Isoform-levelR01LM011297 · NLM · WISTAR INSTITUTE · PI DAVULURI, RAMANA V · 2013 to 2020
$2.4M
NLM NIH HHS R01 LM011297
6 · The paper itself

Abstract

CNS Primitive Neuroectodermal tumors (CNS-PNETs) are members of the embryonal family of malignant childhood brain tumors, which remain refractory to current therapeutic treatments. Current paradigm of brain tumorigenesis implicates brain tumor-initiating cells (BTIC) in the onset of tumorigenesis and tumor maintenance. However, despite their significance, there is currently no comprehensive characterization of CNS-PNETs BTICs. Recently, we described an animal model of CNS-PNET generated by orthotopic transplantation of human Radial Glial (RG) cells - the progenitor cells for adult neural stem cells (NSC) - into NOD-SCID mice brain and proposed that BTICs may play a role in the maintenance of these tumors. Here we report the characterization of BTIC lines derived from this CNS-PNET animal model. BTIC's orthotopic transplantation generated highly aggressive tumors also characterized as CNS-PNETs. The BTICs have the hallmarks of NSCs as they demonstrate self-renewing capacity and have the ability to differentiate into astrocytes and early migrating neurons. Moreover, the cells demonstrate aberrant accumulation of wild type tumor-suppressor protein p53, indicating its functional inactivation, highly up-regulated levels of onco-protein cMYC and the BTIC marker OCT3/4, along with metabolic switch to glycolysis - suggesting that these changes occurred in the early stages of tumorigenesis. Furthermore, based on RNA- and DNA-seq data, the BTICs did not acquire any transcriptome-changing genomic alterations indicating that the onset of tumorigenesis may be epigenetically driven. The study of these BTIC self-renewing cells in our model may enable uncovering the molecular alterations that are responsible for the onset and maintenance of the malignant PNET phenotype.

Indexed as

brain tumor-initiating cellsCNS-PNET animal modelgene signatureradial gliaRNA/DNA-seq

Identifiers

PMID29568390
PMCPMC5862611
OpenAlexW2790004239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.